Parsons Capital Management Inc. RI Has $3.44 Million Stock Position in Eli Lilly And Co (NYSE:LLY)

Parsons Capital Management Inc. RI reduced its position in Eli Lilly And Co (NYSE:LLY) by 1.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 31,025 shares of the company’s stock after selling 412 shares during the period. Parsons Capital Management Inc. RI’s holdings in Eli Lilly And Co were worth $3,437,000 as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of LLY. Thoroughbred Financial Services LLC lifted its stake in Eli Lilly And Co by 11,124.4% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 854,403 shares of the company’s stock valued at $85,440,000 after purchasing an additional 846,791 shares during the last quarter. Bessemer Group Inc. lifted its stake in Eli Lilly And Co by 2,354.5% in the 2nd quarter. Bessemer Group Inc. now owns 569,510 shares of the company’s stock valued at $63,096,000 after purchasing an additional 546,307 shares during the last quarter. Goelzer Investment Management Inc. lifted its stake in Eli Lilly And Co by 1,345.5% in the 1st quarter. Goelzer Investment Management Inc. now owns 312,151 shares of the company’s stock valued at $40,505,000 after purchasing an additional 290,557 shares during the last quarter. Stevens Capital Management LP lifted its stake in Eli Lilly And Co by 3,550.1% in the 2nd quarter. Stevens Capital Management LP now owns 273,389 shares of the company’s stock valued at $30,289,000 after purchasing an additional 265,899 shares during the last quarter. Finally, Schafer Cullen Capital Management Inc lifted its stake in Eli Lilly And Co by 30.3% in the 2nd quarter. Schafer Cullen Capital Management Inc now owns 1,030,446 shares of the company’s stock valued at $111,587,000 after purchasing an additional 239,590 shares during the last quarter. Institutional investors and hedge funds own 79.48% of the company’s stock.

LLY has been the subject of several research reports. Zacks Investment Research downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 21st. Edward Jones upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price objective for the company in a research report on Tuesday, April 23rd. BMO Capital Markets raised their price objective on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Goldman Sachs Group initiated coverage on shares of Eli Lilly And Co in a research report on Tuesday, May 28th. They set a “buy” rating and a $135.00 price objective for the company. Finally, ValuEngine downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Nine analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $123.49.

Shares of LLY traded down $0.28 during mid-day trading on Thursday, hitting $110.01. 121,541 shares of the company’s stock were exchanged, compared to its average volume of 3,974,435. Eli Lilly And Co has a 52 week low of $102.08 and a 52 week high of $132.13. The stock has a 50-day moving average of $110.66. The stock has a market capitalization of $109.60 billion, a price-to-earnings ratio of 19.83, a price-to-earnings-growth ratio of 2.01 and a beta of 0.19. The company has a debt-to-equity ratio of 4.98, a quick ratio of 0.87 and a current ratio of 1.13.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Tuesday, July 30th. The company reported $1.50 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The company had revenue of $5.64 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the firm earned $1.48 earnings per share. The business’s revenue for the quarter was up .9% on a year-over-year basis. Sell-side analysts forecast that Eli Lilly And Co will post 5.72 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a dividend of $0.645 per share. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $2.58 annualized dividend and a dividend yield of 2.35%. Eli Lilly And Co’s dividend payout ratio is presently 46.49%.

In related news, VP Michael J. Harrington sold 16,000 shares of Eli Lilly And Co stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $116.72, for a total value of $1,867,520.00. Following the transaction, the vice president now directly owns 110,300 shares of the company’s stock, valued at $12,874,216. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Joshua L. Smiley acquired 426 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The stock was purchased at an average cost of $118.03 per share, for a total transaction of $50,280.78. Following the completion of the purchase, the chief financial officer now directly owns 30,410 shares of the company’s stock, valued at $3,589,292.30. The disclosure for this purchase can be found here. 0.11% of the stock is currently owned by company insiders.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: What is meant by a buy rating?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.